Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Recurrence 1Prostatic Neoplasms 1Neoplasm Metastasis 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 143pembrolizumab 129Sunitinib 127Bevacizumab 71Everolimus 70Sorafenib 68cabozantinib 64Ipilimumab 61pazopanib 58Axitinib 57aldesleukin 51Magnetic Resonance Spectroscopy 43Cyclophosphamide 40Interleukin-2 38lenvatinib 36Radiosurgery 36Specimen Handling 33Interferon-alpha 32atezolizumab 29belzutifan 24temsirolimus 23Gemcitabine 23fludarabine phosphate 22Radiotherapy 18Interferon alpha-2 18Biopsy 18fludarabine 17durvalumab 17avelumab 17Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Renal Cell × GPI0100 × Clear all
NCT00485563 2012-03-08

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Endocyte

Phase 2 Terminated
12 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡